Công nghệ đột phá của RevitalVision là liệu pháp duy nhất đã được chứng minh lâm sàng và được FDA chấp thuận với tuyên bố về hiệu quả cải thiện thị lực ở người lớn bị nhược thị, ảnh hưởng đến 2% -5% dân số thế giới. Nhược thị là nguyên nhân số 1 gây suy giảm thị lực từ khi còn nhỏ cho đến khi 40 tuổi và được coi là không thể điều trị được sau 9 tuổi.
The technology is also effective in improving vision in a number of other visual impairments and conditions. RevitalVision provides additional significant vision improvement beyond what is currently available by only treating the eyes. The average vision improvement is 2.5 lines on the visual acuity chart, and 100% in contrast sensitivity (about 20% - 25% vision improvement). Most amblyopic patients also improve stereo acuity and binocular function.
Công nghệ này cũng có hiệu quả trong việc cải thiện thị lực ở một số bệnh và tình trạng suy giảm thị lực khác. RevitalVision cung cấp thêm cải thiện thị lực đáng kể ngoài những gì hiện có bằng cách chỉ điều trị mắt. Mức độ cải thiện thị lực trung bình là 2,5 dòng trên biểu đồ thị lực, và 100% về độ nhạy tương phản (cải thiện thị lực khoảng 20% - 25%). Hầu hết các bệnh nhân nhược thị cũng cải thiện thị lực âm thanh nổi và chức năng hai mắt.
Nhóm của chúng tôi bao gồm các chuyên gia y tế và các chuyên gia đa lĩnh vực cùng giải quyết nhu cầu của hàng trăm triệu người trên toàn thế giới mắc các chứng khiếm thị khác nhau và cho đến nay vẫn chưa có giải pháp thay thế hiệu quả nào để cải thiện tình trạng của họ.
Clinical Service Manager
A Certified Optometrist graduated Optometry studies at Hadassah academic college of optometry and visual science. Lena has extensive clinical experience in clinical optometry, and with RevitalVision therapy. Lena specializes in geriatric and in low vision patients.
Founder & CEO
Over 20 years’ experience in senior executive positions in the medical device industry. Past positions includes sales manager
at J&J medical, Business Unit Manager at Boston Scientific, VP sales Asia Pacific at Flight Medical Innovations Ltd.
Yair holds a Bachelor’s degree in political science from Bar Ilan University, and studied for MBA at the Israeli branch of
Henley Brunel business college of West London.
Senior Software Engineer. Graduated software engineering and MBA studies from the TECHNION – Israel Institute of Technology. Served as a software engineer in the IDF (Israel Defense Forces), followed by a senior software engineer position at the Israeli Prime Minister office.
Scientific & Clinical Advisor
Senior pediatric ophthalmologist surgeon. Head of strabismus & pediatric ophthalmology unit at Assaf Harofe Medical Center, Israel. Former president of the Israeli association of strabismus and pediatric ophthalmology.
Prof. (Full member) in Tel Aviv University. Member of the managing committee of the World Society of Pediatric Ophthalmology and Strabismus. A member of the American – Academy of Pediatric Ophthalmology and Strabismus.
Experienced Medical Device executive, with 3 consecutive exits. Current CEO of Orthospace, that was sold to Stryker (2019) for 220$ million. Four years earlier, Itay sold Orthospace to an American investment fund – Innova Health. Itay founded and managed Surgical Structure Ltd, and sold the company to Devol Inc. Itay holds a BA in Economics from Ruppin Academy College, and MBA from the College of Management, Israel.
Dr Amir Belson is a serial entrepreneur, a founder of 12 different companies. He is the founder of Neoguide Systems, a robotic endoscopy company that was acquired by Intuitive Surgical in 2009, Vascular Pathways, a vascular intervention company which was acquired by C R Bard in 2014, Zipline Medical, a wound closure company which was acquired by Stryker in 2019, Qool Therapeutics, a minimally invasive therapeutic hypothermia technology company, Radiaction Medical, a CE mark approved radiation protection medical device company, Embolibe, which develops proprietary total body embolic protection technology, Modular Surgical which develops new minimally invasive surgery technology, and PAFA, that develops atrial fibrillation ablation technology.
Dr. Belson also serves as board director of Rambam Tech, Plantera Lab, Relimetrics and QT Vascular.
Belson graduated cum laude from the school of medicine of the Technion, Israel Institute of Technology, in Haifa, Israel. He did his pediatric residency at Dana Children’s Hospital in Tel Aviv and his pediatric nephrology fellowship at Lucile Packard Children’s Hospital at Stanford University. Belson also spent one year as a research fellow with the Bio-Design Innovation Program at Stanford.
He is the author of 34 medical papers and abstracts and has more than 500 issued and pending patents.
Founder and former CEO of Orca Surgical, an ophthalmic medical device startup. A Certified Optometrist, graduated from the Institute for Research & Studies in Optics and Optometry, in Vidi, Italy. Yariv is well- experienced & well connected to Industry KOL’s.
Founder & CEO of EyeBlink, founder and former CEO of Orca Surgical, ophthalmic medical device startups. A Certified Optometrist, graduated from the Institute for Research & Studies in Optics and Optometry, in Vidi, Italy.
Clinical & Sales Specialist
Certified Optometrist BSc, graduated optometry studies at Bar Ilan University. Efrat has rich clinical experience working in optometry clinics, as well as entrepreneur background.